Gilead Sciences s.r.o. secures contract for Antivirals for Systemic Use - antivirals for systemic use - HDV HEPCLUDEX I

Czechia, May 14 -- Czechia based Gilead Sciences s.r.o. has secured contract from Institut klinicke a experimentalni mediciny for Antivirals for Systemic Use - antivirals for systemic use - HDV HEPCLUDEX I. The value of the contract is worth 1711716400 CZK.

Published by HT Digital Content Services with permission from Pivotal Sources....